Supplementary Table S1. HR of statins and observed variables for NODM

Comparison Variables HR 95% CI p-value

Comparison 1*

(statin-exposed group vs. matched statin non-exposed group)

Exposure to statin 1.641 1.095–2.458 0.016

Age 1.006 0.991–1.021 0.446

Gender (male) 0.961 0.666–1.387 0.833

1

Baseline glucose 1.016 1.012–1.019 <0.001

Hypertension 3.489 1.751–6.950 <0.001

BMI (≥25) 1.963 1.358–2.839 <0.001

Comparison 2*

(individual statin-exposed group vs. matched statinnon-exposed group)

Atorvastatin 1.660 1.022–2.698 0.041

Fluvastatin 1.489 0.263–8.419 0.652

Pitavastatin 0.879 0.098–7.855 0.908

Pravastatin 1.936 0.873–4.294 0.104

Rosuvastatin 2.394 0.965–5.942 0.060

Simvastatin 2.494 1.019–6.100 0.045

Comparison 3*

(within-class comparison)

Atorvastatin 1.076 0.733–1.578 0.710

Fluvastatin 1.299 0.413–4.089 0.655

Pitavastatin 0.365 0.051–2.613 0.316

Pravastatin 0.936 0.540–1.623 0.813

Rosuvastatin 0.871 0.495–1.533 0.631

Simvastatin 1.347 0.810–2.240 0.251*Age, gender, baseline glucose level, and body mass index (BMI) were adjusted. HR, hazard ratio; 95% CI, 95%

confidence interval; BMI, body mass index.

2